KDMNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases...

Stats
本日の出来高	10.42M
平均出来高	10.03M
時価総額	0.00
EPS	$-0.200 ( 2021-11-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.32
ATR14	$0.213 (2.24%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-09	Waksal Harlan	Sell	177 945	Common Stock
2021-11-09	Waksal Harlan	Buy	655 000	Stock Appreciation Right
2021-11-09	Waksal Harlan	Buy	982 500	Performance Stock Option(right to buy)
2021-11-09	Waksal Harlan	Buy	1 350 000	Stock Option (right to buy)
2021-11-09	Waksal Harlan	Buy	2 000 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 93 transactions
Buy: 16 325 233 \| Sell: 4 159 124

ボリューム相関

長: 0.23 (neutral)

短: 0.86 (strong)

Signal:(72.9) Same movement expected

Kadmon Holdings Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Kadmon Holdings Inc 相関 - 通貨/商品

0.83
( strong )

0.90
( very strong )

-0.86
( strong negative )

0.80
( moderate )

-0.57
( weak negative )

Kadmon Holdings Inc 財務諸表

Annual	2020
収益:	$8.29M
総利益:	$6.29M (75.86 %)
EPS:	$-0.670

FY	2020
収益:	$8.29M
総利益:	$6.29M (75.86 %)
EPS:	$-0.670

FY	2019
収益:	$5.10M
総利益:	$3.81M (74.70 %)
EPS:	$-0.480

FY	2018
収益:	$1.40M
総利益:	$714 000 (51.15 %)
EPS:	$-0.580

Financial Reports:

No articles found.

Kadmon Holdings Inc

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.